

Development of molecular targeted drug for malignant tumor using proteomics

Yasuhiro MIYAKE

Department of Gastroenterology and Hepatology, Okayama University Hospital

Anti-ribosomal protein L29 (RPL29) antibody discovered from human sera

Investigation of anti-tumor immune response in human

Discovery of new cancer antigen

Development of First-In-Class Anti-Cancer Agent

Fig. 1. Serum anti-RPL29 levels and overall survival.





Fig. 2. Mouse anti-human RPL29 antibody inhibits Huh7 cell proliferation.



- Higher serum anti-RPL29 antibody levels are associated with the better prognosis of cancer patients (Fig. 1).
- Mouse anti-human RPL29 antibodies potently inhibit the proliferation of cancer cells via down-regulation of Wnt/ β -Catenin signaling pathway (Fig. 2, 3).

Fig.3. Changes in signal transduction molecules

